<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876067</url>
  </required_header>
  <id_info>
    <org_study_id>AssuitUlotfallah</org_study_id>
    <nct_id>NCT03876067</nct_id>
  </id_info>
  <brief_title>The Cardioprotective Effects of Adding Ozone To Cardioplegic Solution in Adult Cardiac Surgery</brief_title>
  <official_title>The Cardioprotective Effects of Adding Ozone To Cardioplegic Solution in Adult Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      forty patients with age ranged between 40-70 years undergoing elective coronary artery bypass&#xD;
      graft surgery with cardiopulmonary bypass will be included, they will divided into two&#xD;
      groups.&#xD;
&#xD;
      Ozone Group: in which Ozone will be added to cold blood cardioplegia. Control Group: in which&#xD;
      in which only cold blood cardioplegia&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Pattern of recovery of myocardium after declamping of Aorta&#xD;
&#xD;
        1. Time of cardiac rhythm return after declamping.&#xD;
&#xD;
        2. type of cardiac rhythm after declamping and rate of DC use.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      A-cardiac parameters&#xD;
&#xD;
        -  Post operative inotropic score&#xD;
&#xD;
        -  Incidence of post operative cardiac dysrhythmias&#xD;
&#xD;
        -  postoperative ejection fraction (EF)&#xD;
&#xD;
        -  Postoperative parameters of myocardial ischaemia&#xD;
&#xD;
        -  a- Troponin levels&#xD;
&#xD;
        -  b-Pro BNP&#xD;
&#xD;
        -  • Histopathology of myocardial sample for detection of myocyte cellular edema as a&#xD;
           marker of ischemic changes.&#xD;
&#xD;
      B-non cardiac parameters:&#xD;
&#xD;
        1. inflammatory markers 1. CRP 2. L\N 3. P\N&#xD;
&#xD;
        2. ICU stay&#xD;
&#xD;
        3. hospital stay&#xD;
&#xD;
        4. morbidity and mortality&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ozone Administration Protocol&#xD;
&#xD;
      Our procedures for O3T application in CBP surgery conform to international guidelines of the&#xD;
      ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:&#xD;
&#xD;
      50mL of blood drawn by vacuum from the patient central catheter into a sterile blood&#xD;
      transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries,&#xD;
      Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume&#xD;
      ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the&#xD;
      venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was&#xD;
      immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by&#xD;
      Medozon compact generator (Herrmann Apparatebau GmbH, Germany).&#xD;
&#xD;
      The gas is immediately and continuously mixed with the blood in the bag for at least 5 min&#xD;
      and with gentle rotating movement to avoid foaming. Due to the blood viscosity, the gas&#xD;
      mixture does not instantaneously come into contact with the whole blood mass, thus this&#xD;
      mixing time is necessary. During these 5 min of mixing, the ozone totally reacted with both&#xD;
      the potent antioxidants of plasma and the unsaturated lipids bound to albumin, generating&#xD;
      asmall amount of hydrogen peroxide and alkenals. These two messengers were responsible for&#xD;
      eliciting crucial biochemical reactions on both erythrocytes and within cells. At this point,&#xD;
      the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons&#xD;
      cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic&#xD;
      solution&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
      The patient will be excluded from the study if he has any of the following:&#xD;
&#xD;
        -  left ventricular ejection fraction&lt; 40%&#xD;
&#xD;
        -  diabetic or other metabolic disorders,&#xD;
&#xD;
        -  use of left ventricular assist devices,&#xD;
&#xD;
        -  Renal failure or on hemodialysis&#xD;
&#xD;
        -  Hepatic dysfunction&#xD;
&#xD;
        -  Hypothyroidism&#xD;
&#xD;
        -  implanted pacemaker&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of cardiac rhythm</measure>
    <time_frame>one hour</time_frame>
    <description>Time of cardiac rhythm return after declamping.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>type of cardiac rhythm</measure>
    <time_frame>one hour</time_frame>
    <description>type of cardiac rhythm after declamping and rate of DC use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post operative inotropic score</measure>
    <time_frame>two weeks</time_frame>
    <description>Post operative inotropic score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post operativecardiac dysrhythmias</measure>
    <time_frame>two weeks</time_frame>
    <description>Incidence of post operativecardiac dysrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative ejection fraction (EF)</measure>
    <time_frame>one month</time_frame>
    <description>postoperative ejection fraction (EF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative parameters of myocardial ischaemia</measure>
    <time_frame>two weeks</time_frame>
    <description>Troponin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>two weeks</time_frame>
    <description>ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>two weeks</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Ozone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in which Ozone will be added to cold blood cardioplegia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>: in which in which only cold blood cardioplegia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozone</intervention_name>
    <description>Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:&#xD;
50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).&#xD;
At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution</description>
    <arm_group_label>Ozone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cardioplegic Solutions</intervention_name>
    <description>in which in which only cold blood cardioplegia</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients undergoing elective CABG surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • left ventricular ejection fraction&lt; 40%&#xD;
&#xD;
               -  diabetic or other metabolic disorders,&#xD;
&#xD;
               -  use of left ventricular assist devices,&#xD;
&#xD;
               -  Renal failure or on hemodialysis&#xD;
&#xD;
               -  Hepatic dysfunction&#xD;
&#xD;
               -  Hypothyroidism&#xD;
&#xD;
               -  implanted pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 10, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 16, 2019</last_update_submitted>
  <last_update_submitted_qc>March 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Israa mohamed lotfallah</investigator_full_name>
    <investigator_title>assistant lecture assiut university hospital principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardioplegic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

